{"disease":{"id":"systemic-lupus","name":"systemic lupus"},"drugs":{"marketed":[{"drug_id":"benlysta","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Benlysta","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"Tumor necrosis factor ligand superfamily member 13B","drug_class":"","quality_score":24,"revenue":"1200","mechanism":null},{"drug_id":"belimumab","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lymphostat B","generic_name":"BELIMUMAB","company_name":"Human Genome Sciences Inc.","drug_phase":"marketed","molecular_target":"Tumor necrosis factor ligand superfamily member 13B","drug_class":"B Lymphocyte Stimulator-specific Inhibitor [EPC]","quality_score":59,"revenue":"1100","mechanism":"Belimumab works by blocking the B Lymphocyte Stimulator, a protein that can contribute to the autoimmune response in Systemic lupus erythematosus."},{"drug_id":"anifrolumab","indication_name":"Moderate to severe systemic lupus erythematosus (SLE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Saphnelo","generic_name":"ANIFROLUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor 1","drug_class":"Type I Interferon Receptor Antagonist [EPC]","quality_score":59,"revenue":"700","mechanism":"Saphnelo blocks the action of interferon alpha/beta, a protein that triggers an immune response."},{"drug_id":"hydrocortisone-succinate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydroxychloroquine-pill","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"hydroxychloroquine-pill","company_name":"Sanofi","drug_phase":"discontinued","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":null,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and modulating the immune system to treat autoimmune diseases."},{"drug_id":"azathioprine","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imuran","generic_name":"AZATHIOPRINE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Purine Antimetabolite [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"prasterone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intrarosa","generic_name":"PRASTERONE","company_name":"","drug_phase":"marketed","molecular_target":"Sex hormone-binding globulin","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"advanced-therapy-only-without-dietary-intervention","indication_name":"Bone Marrow-Derived Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Advanced therapy only without dietary intervention","generic_name":"advanced-therapy-only-without-dietary-intervention","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"various cell types","drug_class":"advanced therapy","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednison","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"anifrolumab-fnia","indication_name":"Moderate to severe systemic lupus erythematosus (SLE)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SAPHNELO","generic_name":"ANIFROLUMAB-FNIA","company_name":"ASTRAZENECA AB","drug_phase":"marketed","molecular_target":"Interferon alpha/beta receptor 1","drug_class":"Type I Interferon Receptor Antagonist [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"intrarosa","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Intrarosa","company_name":"Center for Vulvovaginal Disorders","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"oral-14c-pf-06821497","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral [14C] PF-06821497","generic_name":"oral-14c-pf-06821497","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"chloroquine","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aralen","generic_name":"CHLOROQUINE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sigma non-opioid intracellular receptor 1","drug_class":"Antimalarial","quality_score":65,"revenue":null,"mechanism":"Aralen works by accumulating in the acidic compartments of the malaria parasite, disrupting its metabolism and ultimately leading to its death."},{"drug_id":"hydroxychloroquine","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."},{"drug_id":"betamethasone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxychloroquin","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxychloroquin","company_name":"Children's Hospital of Fudan University","drug_phase":"marketed","molecular_target":"Transmembrane protein 97, Alpha-1D adrenergic receptor, Alpha-2A adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"dehydroepiandrosterone","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Dehydroepiandrosterone","company_name":"National Institute of Dental and Craniofacial Research (NIDCR)","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin, Beta-glucuronidase, Glucose-6-phosphate 1-dehydrogenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dexamethasone-phosphate","indication_name":"Systemic lupus erythematosus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxychloroquine","indication_name":"Systemic lupus erythematosus treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hydroxychloroquine Sulfate","generic_name":"HYDROXYCHLOROQUINE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Toll-like receptor 9","drug_class":"Antimalarial","quality_score":75,"revenue":null,"mechanism":"Hydroxychloroquine Sulfate works by interfering with the replication of malaria parasites and reducing inflammation in the body."}],"pipeline":[],"offLabel":[],"totalMarketed":32,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07431775","title":"Saphnelo Use in Females of Child-bearing Potential","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":26000000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04239521","title":"The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata","phase":"","overall_status":"COMPLETED","enrollment_count":51955,"lead_sponsor_name":"Momentum Data","has_results":false},{"nct_id":"NCT06927219","title":"Research Accelerated by You Lupus Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Lupus Foundation of America","has_results":false},{"nct_id":"NCT03138941","title":"Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Monash University","has_results":false},{"nct_id":"NCT07077304","title":"EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT01705977","title":"Belimumab Assessment of Safety in SLE","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":4019,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03802188","title":"Hydroxychloroquine in Systemic Lupus Erythematosus","phase":"","overall_status":"UNKNOWN","enrollment_count":3700,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT07000110","title":"Anifrolumab Malignancy and Serious Infections Study","phase":"","overall_status":"RECRUITING","enrollment_count":3195,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01729455","title":"Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry","phase":"","overall_status":"COMPLETED","enrollment_count":3138,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03142412","title":"Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"DxTerity Diagnostics","has_results":false},{"nct_id":"NCT05879419","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2005,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT00001372","title":"Study of Systemic Lupus Erythematosus","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","has_results":false},{"nct_id":"NCT03735238","title":"Implementing the Decision-Aid for Lupus (IDEAL Strategy)","phase":"","overall_status":"COMPLETED","enrollment_count":1895,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT04747288","title":"Objective Measurement With TCM Pattern for AIDDES","phase":"","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT03370263","title":"BENLYSTA® Special Drug Use Investigation","phase":"","overall_status":"COMPLETED","enrollment_count":1514,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT07175610","title":"LUpus Eritematoso Sistemico NETwork and Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Società Italiana di Allergologia, Asma e Immunologia Clinica","has_results":false},{"nct_id":"NCT04749875","title":"Study of Leukocyte Populations in Patients With Chronic Inflammatory","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03843125","title":"A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1147,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT00055055","title":"Study of Families With Twins or Siblings Discordant for Rheumatic Disorders","phase":"","overall_status":"COMPLETED","enrollment_count":1056,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT04604990","title":"National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"King Saud University","has_results":false},{"nct_id":"NCT06804057","title":"CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"CorEvitas","has_results":false},{"nct_id":"NCT07000916","title":"Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Université Catholique de Louvain","has_results":false},{"nct_id":"NCT03276923","title":"Maternal Autoimmune Disease Research Alliance (MADRA) Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06698900","title":"This Project Aims to Understand the Needs of Rheumatologists and Other Specialties in the Care of Patients With SLE","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07005479","title":"Long-Term Outcomes in SLE at Peking University People's Hospital","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03348774","title":"Scrutinizing the Heterogeneity of SLE: Defining Phenotypes","phase":"","overall_status":"UNKNOWN","enrollment_count":950,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT07102030","title":"Subgrouping SLE - a New Approach to Understand the Pathogenesis and Improve Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Region Stockholm","has_results":false},{"nct_id":"NCT02782039","title":"Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)","phase":"","overall_status":"COMPLETED","enrollment_count":868,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05352919","title":"An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":864,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT01484496","title":"A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":839,"lead_sponsor_name":"Human Genome Sciences Inc., a GSK Company","has_results":true},{"nct_id":"NCT01283139","title":"A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":834,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT03616912","title":"A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":830,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT03189875","title":"Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)","phase":"","overall_status":"COMPLETED","enrollment_count":830,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03616964","title":"A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":778,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT04976322","title":"A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":760,"lead_sponsor_name":"UCB Biopharma SRL","has_results":false},{"nct_id":"NCT00712933","title":"A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":738,"lead_sponsor_name":"Human Genome Sciences Inc., a GSK Company","has_results":true},{"nct_id":"NCT01345253","title":"GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":709,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07209540","title":"European LUpuS Inception-Cohort Developing initiATivE","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":700,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT03952624","title":"Patient-Centered Assessment of Symptoms and Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":692,"lead_sponsor_name":"National Center for Complementary and Integrative Health (NCCIH)","has_results":false},{"nct_id":"NCT03480529","title":"Monitoring the IMmUological TOXicity of Drugs","phase":"","overall_status":"COMPLETED","enrollment_count":662,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT06599658","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":660,"lead_sponsor_name":"McGill University Health Centre/Research Institute of the McGill University Health Centre","has_results":false},{"nct_id":"NCT00342095","title":"Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study","phase":"","overall_status":"COMPLETED","enrollment_count":640,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT06056778","title":"The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)","phase":"","overall_status":"COMPLETED","enrollment_count":628,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07049653","title":"Anifrolumab Pregnancy Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":627,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06759519","title":"Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia","phase":"","overall_status":"COMPLETED","enrollment_count":621,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05714930","title":"LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus","phase":"NA","overall_status":"RECRUITING","enrollment_count":606,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT04942314","title":"Practice of Treat-to-target on Pediatric Systemic Lupus Erythematosus: a Two-center Retrospective Study","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Jia Deng","has_results":false},{"nct_id":"NCT03430388","title":"Yellow Fever Vaccine in Patients With Rheumatic Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT04345159","title":"Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease","phase":"","overall_status":"COMPLETED","enrollment_count":572,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}